Biotechnology company developing personalized cancer immunotherapies based on individual patient genetics.
Gritstone bio, Inc. is a dynamic clinical-stage biotechnology company focused on advancing cutting-edge immunotherapies targeting various cancers and infectious diseases. At the forefront of its innovative pipeline is GRANITE, a neoantigen-based immunotherapy designed to combat solid tumors such as metastatic non-small cell lung cancer, gastroesophageal, bladder, microsatellite stable colorectal cancers, among others.
In addition to GRANITE, Gritstone bio, Inc. is advancing SLATE, an off-the-shelf immunotherapy candidate aimed at treating prevalent solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and tumors positive for shared neoantigens.
The company is also actively developing CORAL, a SARS-CoV-2 vaccine platform engineered to deliver spike and other T cell epitopes for enhanced protection and broader immunity against emerging SARS-CoV-2 variants. Furthermore, Gritstone bio, Inc. is pioneering a therapeutic vaccine candidate designed to potentially cure human immunodeficiency virus (HIV) infection.
Formerly known as Gritstone Oncology, Inc., the company rebranded to Gritstone bio, Inc. in May 2021 to reflect its broadened focus and expanded scope of therapeutic applications. Since its inception in 2015 and headquartered in Emeryville, California, Gritstone bio, Inc. continues to forge strategic collaborations with industry leaders such as bluebird bio, Inc. and Gilead Sciences, Inc., while also leveraging key partnerships like its licensing agreement with Genevant Sciences GmbH to drive forward its groundbreaking research and development initiatives.